Phenanthroline

Phenanthroline

SCHEMBL2813173

Cl[Pd].c1cnc2c(c1)ccc1cccnc12

nearest known ligand 0.84

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 5/20 0.84
CCR8 P51685 5/20 0.84
LMNA P02545 4/20 0.84
CCR5 P51681 3/20 0.84
KDM4E B2RXH2 3/20 0.84
MMP2 P08253 2/20 0.84
TSHR P16473 2/20 0.84
MAPT P10636 2/20 0.84
HTT P42858 2/20 0.84
SMN1; SMN2 Q16637 2/20 0.84
TDP1 Q9NUW8 2/20 0.84
GMNN O75496 1/20 0.84
TP53 P04637 1/20 0.84
HSP90AA1 P07900 1/20 0.84
CYP3A4 P08684 1/20 0.84
CYP2D6 P10635 1/20 0.84
MMP9 P14780 1/20 0.84
ALOX15 P16050 1/20 0.84
NFKB1 P19838 1/20 0.84
MMP8 P22894 1/20 0.84

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phenanthroline SCHEMBL29354015 0.92 CCR1 (1.00) CCR1CCR8LMNACCR5KDM4E
Phenanthroline SCHEMBL29367277 0.92 CCR1 (1.00) CCR1CCR8LMNACCR5KDM4E
Phenanthroline SCHEMBL8845760 0.92 CCR1 (1.00) CCR1CCR8LMNACCR5KDM4E
Phenanthroline SCHEMBL8312 0.92 CCR1 (1.00) CCR1CCR8LMNACCR5KDM4E
Phenanthroline SCHEMBL30945289 0.90 CCR1 (0.84) CCR1CCR8LMNACCR5KDM4E
Phenanthroline SCHEMBL22982126 0.89 CCR1 (0.94) CCR1CCR8LMNACCR5KDM4E
Phenanthroline SCHEMBL21044608 0.89 CCR1 (0.94) CCR1CCR8LMNACCR5KDM4E
Phenanthroline SCHEMBL725644 0.89 CCR1 (0.94) CCR1CCR8LMNACCR5KDM4E
Phenanthroline SCHEMBL22462277 0.89 CCR1 (0.94) CCR1CCR8LMNACCR5KDM4E
Phenanthroline SCHEMBL21300488 0.89 CCR1 (0.94) CCR1CCR8LMNACCR5KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103570697-B The method for preparing vilazodone and its intermediate 江苏先声药业有限公司 2017-09-15 CN claimed
CN-103664911-B The method for preparing vilazodone and its intermediate 江苏先声药业有限公司 2017-09-15 CN claimed
CN-104341370-A Preparation method of cetilistat SHANDONG CHUANGXIN PHARMACEUTICAL RES AND DEV CO LTD 2015-02-11 CN claimed
CN-103664911-A Method of preparing vilazodone and intermediate thereof JIANGSU SIMCERE PHARMACEUTICAL 2014-03-26 CN claimed
CN-103570697-A Method for preparing vilazodone and intermediate thereof JIANGSU SIMCERE PHARMACEUTICAL 2014-02-12 CN claimed
CN-111320526-B Method for preparing hexafluorobutadiene 浙江蓝天环保高科技股份有限公司 2023-09-05 CN disclosed
CN-109715593-B Method for removing or recovering 2-alkoxyethanol and method for producing (2-alkoxyethyl) vinyl ether 丸善石油化学株式会社 2022-05-31 CN disclosed
US-11247961-B2 Me 1 hod for removing or collecting 2-alkoxyethanol, and method for producing (2-alkoxyethyl) vinyl ether MARUZEN PETROCHEMICAL CO., LTD. (JP) 2022-02-15 US disclosed
EP-3514133-B1 METHOD FOR REMOVING OR COLLECTING 2-ALKOXYETHANOL, AND METHOD FOR PRODUCING (2-ALKOXYETHYL) VINYL ETHER MARUZEN PETROCHEM CO LTD (JP) 2020-11-25 EP disclosed
CN-111320526-A Method for preparing hexafluorobutadiene 浙江蓝天环保高科技股份有限公司 2020-06-23 CN disclosed
EP-3514133-A1 METHOD FOR REMOVING OR COLLECTING 2-ALKOXYETHANOL, AND METHOD FOR PRODUCING (2-ALKOXYETHYL) VINYL ETHER Maruzen Petrochemical Co., Ltd. (JP) 2019-07-24 EP disclosed
US-20190210949-A1 METHOD FOR REMOVING OR COLLECTING 2-ALKOXYETHANOL, AND METHOD FOR PRODUCING (2-ALKOXYETHYL) VINYL ETHER MARUZEN PETROCHEMICAL CO., LTD. (JP) 2019-07-11 US disclosed
CN-103664911-B The method for preparing vilazodone and its intermediate 江苏先声药业有限公司 2017-09-15 CN disclosed
CN-103570697-B The method for preparing vilazodone and its intermediate 江苏先声药业有限公司 2017-09-15 CN disclosed
CN-104341370-B Preparation method of cetilistat 山东创新药物研发有限公司 2017-02-22 CN disclosed
CN-104341370-A Preparation method of cetilistat SHANDONG CHUANGXIN PHARMACEUTICAL RES AND DEV CO LTD 2015-02-11 CN disclosed
CN-103664911-A Method of preparing vilazodone and intermediate thereof JIANGSU SIMCERE PHARMACEUTICAL 2014-03-26 CN disclosed
CN-103635480-A Palladium complex and method for producing same, method for producing vinyl ether compound, and method for recovering palladium complex DAICEL CORP 2014-03-12 CN disclosed
CN-103570697-A Method for preparing vilazodone and intermediate thereof JIANGSU SIMCERE PHARMACEUTICAL 2014-02-12 CN disclosed
US-20100249465-A1 PROCESS FOR PRODUCTION OF HIGH-PURITY VINYL ETHER MARUZEN PETROCHEMICAL CO., LTD. (JP) 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249465-A1 PROCESS FOR PRODUCTION OF HIGH-PURITY VINYL ETHER ADH1A, ADH1C, VMP1 CCR1 1623/4885CCR8 2651/4885LMNA 3597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.